Pharmaceutical Industry Articles & Reports - Page 9

A 2026 analyst comparison of Xenium, CosMx, MERSCOPE, Visium HD, and GeoMx DSP spatial biology platforms, covering resolution, throughput, pricing, and benchmarks.

A 2026 comparison of six eCOA/ePRO vendors, Signant Health, Medidata, Clario, YPrime, Suvoda, and Veeva, covering pricing models, FDA/EMA compliance, migration checklists, and market data.

A 2026 analyst comparison of single-use vs stainless steel bioprocessing covering capex/opex crossover points, extractables and leachables validation, market sizing from six research firms, and five named hybrid facility case studies.

Compares leading organ-on-a-chip companies in 2026 including Emulate, MIMETAS, CN Bio, TissUse, and Hesperos, covering platforms, funding, FDA partnerships, and market data.

A 2026 data report on organ-on-a-chip FDA qualification, covering the ISTAND pathway, Emulate's Liver-Chip Letter of Intent, IND cases from Sanofi, Dianthus, and argenx, and FDA Modernization Act 2.0/3.0 status.

A 2026 analyst report on CAR-T manufacturing cost of goods sold, covering per-dose cost estimates from $16,000 vector batches to $616,500 real-world claims costs, vein-to-vein turnaround times, and decentralized manufacturing economics.

A 2026 analyst guide to the decentralized clinical trials technology stack, covering Medable, Signant Health, Castor, THREAD, Veeva and IQVIA, the FDA and EMA regulatory timeline, RBQM, and market data.

A 2026 analyst report on Annex 1 aseptic processing contamination control strategy, covering CCS requirements, RABS vs isolator grade thresholds, FDA warning letter enforcement, and 2023-2024 compliance deadlines.

A 2026 analyst guide to 21 CFR Part 4 combination products, covering CGMP streamlined versus standalone compliance, the QMSR transition effective February 2026, and FDA human factors validation testing requirements.

A 2026 analyst guide to ICH E6(R3) risk-based monitoring requirements, covering quality tolerance limits, central statistical monitoring, key risk indicators, and the EU's 23 July 2025 effective date.

A 2026 analyst guide to self-driving labs in pharma R&D, covering closed-loop experimentation, the AI methods behind it, 12+ named vendors, AstraZeneca's iLab, and Insilico Medicine's autonomous discovery pipeline.

A 2026 analyst report on DSCSA EPCIS exception handling: PDG's five exception categories, GS1 EPCIS 2.0 ErrorDeclaration mechanics, FDA stabilization survey data, and Cardinal Health's historical sampled pilot findings.

A 2026 analyst guide to EU GMP Annex 22, covering its AI explainability and confidence-score requirements, the static-versus-dynamic model scope, PIC/S and FDA enforcement precedent, and a practical implementation checklist.

A 2026 data report on clinical trial protocol amendment frequency and cost, covering Tufts CSDD statistics showing 76% of protocols amended, $141,000-$535,000 median direct costs, and 260-day implementation timelines.

A 2026 analyst guide to list price vs net price for prescription drugs, covering the $416B gross-to-net bubble, PBM rebate and spread pricing mechanics, FTC litigation, and Medicare drug price negotiation data.

A 2026 analyst comparison of All of Us, UK Biobank, N3C, MIMIC-IV, SEER, PCORnet, and TriNetX covering access costs, application steps, dataset scale, and AI training suitability.

A 2026 analyst data report on FDA Form 483 and warning letter statistics, covering year-by-year enforcement trends, country-level data, most-cited GMP observations, and documented case studies.

Analysis of CDER's disclosed AI submission counts from 2016 to 2026, the January 2025 AI credibility guidance, the Elsa review tool, and named case studies as of August 2026.

A 2026 data-driven analysis of 340B program statistics: HRSA's $100 billion 2025 purchase total, covered entity growth, 31,593 contract pharmacies, 41 restricting manufacturers, and the HRSA rebate model pilot.

A 2026 analyst data report on clinical trial diversity statistics covering FDA Diversity Action Plan status, enrollment by race, ethnicity, sex and age, and disease-burden gaps in oncology, cardiology, diabetes and Alzheimer's.

A 2026 analyst report on FDA accelerated approval confirmatory trial status: conversion and withdrawal rates, Project Confirm data, FDORA requirements, the 2020-2026 withdrawal list, and 5 case studies.

A 2026 analyst guide to the Medicare Drug Price Negotiation list, covering all 40 selected drugs across three rounds, negotiated Maximum Fair Prices, CMS savings estimates, and pending litigation.

A 2026 analyst guide to CTMS, eTMF, and LIMS pricing comparing Veeva, Medidata, Oracle, LabWare, Thermo Fisher, and LabVantage, with cost ranges, TCO tables, and 9 named case studies.

A 2026 analyst guide to CMS Open Payments data: 2025 program year totals of $14.67 billion, top pharma and medtech payers, payment categories, state breakdowns, and 5 enforcement case studies.